Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Times Have Changed: FDA Ends ESA REMS Ahead Of First Biosimilars

17 Apr 2017

• By Michael McCaughan

Related Content

'Orphans' Hit Historic High At US FDA; More 'Me-Too' Drugs Urged

17 Dec 2015

Drug Pricing Pundit Gottlieb Likely To Stay In His Lane At FDA

14 Apr 2017

Gottlieb's Confirmation: He's Willing To Disagree With Trump, Sec. Price

06 Apr 2017

Living in a Bipolar World: Implications of the EPO Safety Debate (Part 1)

01 Jul 2007

FDA And ESA Safety: A Conversation With Bob Temple And Ellis Unger

31 May 2010

Biosimilars In 2017: Crowded US FDA Review Queue, Key Legal Decisions

24 Jan 2017

Related Companies

Amgen, Inc.

Johnson & Johnson

Hospira, Inc.

Additional Topics

United States Drug Safety Biosimilars FDA Regulation BioPharmaceutical

More from Drug Safety

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.